TT International’s Pacific Biosciences PACB Stock Holding History

TT International’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-135,000	Closed	-$976K	–	56
2019 Q1	$976K	Buy	+135,000	New	+$976K	0.1%	42

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

TT International's PACB Position: Q2 2019 in Review

TT International sold out of Pacific Biosciences (PACB) in Q2 2019, closing a stake of 135,000 shares — an estimated $976K sold.

TT International first reported a position in PACB in Q1 2019 and held it in 1 quarter. The position peaked at $976K in Q1 2019. 150 funds tracked by Wall St. Rank hold PACB as of Q2 2019.

TT International reported no remaining Pacific Biosciences position as of Q2 2019 after selling out during the quarter.
TT International sold 135,000 Pacific Biosciences shares in Q2 2019, an estimated $976K.
TT International first reported a position in Pacific Biosciences in Q1 2019 and held it in 1 quarter.
TT International's Pacific Biosciences position peaked at $976K in Q1 2019.
150 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2019.

Based on TT International's 13F filing for Q2 2019, filed 12 Aug 2019.